Boehringer Ingelheim opens advanced ADC R&D Center in Basel

SWITZERLAND—Boehringer Ingelheim, through its subsidiary NBE Therapeutics, has inaugurated a state-of-the-art research and development (R&D) facility in Basel, Switzerland, dedicated to advancing antibody-drug conjugates (ADCs).

This CHF 27 million (US$30.5 million) investment marks a significant step in the company’s strategy to transform cancer care by developing innovative treatments that enhance patients’ lives.

The new facility is designed to accelerate the development of next-generation ADCs, targeted therapies that combine antibodies with potent cytotoxic agents to precisely attack tumor cells while minimizing harm to healthy tissues.

This approach offers promising advancements in oncology, aiming to improve the quality of life for cancer patients.

The building spans 1,826 square meters and features energy-efficient designs that meet Swiss sustainability standards, earning the prestigious Gold Certificate from the Deutsche Gesellschaft für Nachhaltiges Bauen.

The R&D center will house a team of 50 scientists supported by administrative and management staff, fostering collaboration within Boehringer Ingelheim’s global network of experts.

NBE Therapeutics CEO Jean Engela emphasized the importance of this facility, stating that it reflects the company’s commitment to delivering breakthrough innovations for people living with cancer.

He expressed confidence that the cutting-edge infrastructure will enable faster development of ADC therapies, ultimately improving patient outcomes.

This initiative builds upon Boehringer Ingelheim’s broader oncology strategy, which includes a licensing agreement with Synaffix B.V. and the opening of another research site in Vienna, Austria, in 2024.

Together, these efforts aim to expand the company’s ADC pipeline and address novel tumor targets.

Karl Penz, CFO of Boehringer Ingelheim’s Innovation Unit and Chairperson of NBE Therapeutics’ board, highlighted Switzerland’s unparalleled biotech ecosystem as a key factor in advancing cancer research.

The local government has also supported NBE Therapeutics’ evolution since its founding in Basel in 2012 and acquisition by Boehringer Ingelheim in 2020.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.